The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.

Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.

Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months. | Vanda Pharmaceuticals is riding a ...

Milsaperidone is an active metabolite of iloperidone ...

The U.S. Food and Drug Administration has approved milsaperidone (Bysanti) tablets as a first-line therapy for adults with schizophrenia and manic or mixed episodes of bipolar I disorder, ...

The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

Bipolar disorder often is initially misdiagnosed because some of its symptoms are similar to other mental illnesses. People who are bipolar experience both intense highs and lows. These severe mood ...

Bipolar disorder, also known as manic depression, is a chronically recurring condition involving moods that swing between the highs of mania and the lows of depression. Depression is by far the most ...